Ferechide Dumitru, Radulescu Daniela
Carol Davila" UMP, Department of Physiology, Bucharest, Romania.
J Med Life. 2009 Jan-Mar;2(1):53-9.
Homocysteine is a sulfurated amino acid used for the synthesis of methionine. The last decade's researches proved that hyperhomocysteinemia is an independent risk factor for atherosclerotic vascular disease. The vascular injury induced by several mechanisms of hyperhomocysteinemia is the hallmark of homocysteine's atherogenic properties. Hyperhomocysteinemia is present in 85% of the patients with chronic renal failure (cardiovascular diseases are the main cause of mortality) and persists after initiating dialysis or after renal transplantation. Although folic therapy or folinic acid therapy reduce homocysteine levels with 20-40% in hemodialysis patients, the effects on cardiovascular morbidity have yet to be proven in future studies.
同型半胱氨酸是一种用于甲硫氨酸合成的含硫氨基酸。过去十年的研究证明，高同型半胱氨酸血症是动脉粥样硬化性血管疾病的一个独立危险因素。高同型半胱氨酸血症通过多种机制诱导的血管损伤是同型半胱氨酸致动脉粥样硬化特性的标志。85%的慢性肾衰竭患者存在高同型半胱氨酸血症（心血管疾病是主要死因），且在开始透析或肾移植后仍持续存在。尽管叶酸疗法或亚叶酸疗法可使血液透析患者的同型半胱氨酸水平降低20% - 40%，但其对心血管发病率的影响仍有待未来研究证实。
